These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20413772)

  • 1. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
    Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
    Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
    Schmainda KM; Prah M; Connelly J; Rand SD; Hoffman RG; Mueller W; Malkin MG
    Neuro Oncol; 2014 Jun; 16(6):880-8. PubMed ID: 24431219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
    Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
    Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
    Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
    Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
    Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
    Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
    Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
    Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
    Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
    Gahramanov S; Muldoon LL; Li X; Neuwelt EA
    Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.
    LaViolette PS; Cohen AD; Prah MA; Rand SD; Connelly J; Malkin MG; Mueller WM; Schmainda KM
    Neuro Oncol; 2013 Apr; 15(4):442-50. PubMed ID: 23382287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
    Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
    Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.